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Background: Data on Human Papilloma virus (HPV) vaccine immune response in sub-Saharan Africa is still sparse
yet such knowledge is critical for optimal implementation and monitoring of HPV vaccines. Our primary objective
was to evaluate levels of anti-HPV-16/18 antibodies and six other ‘high risk’ HPV (hrHPV) types among the
vaccinated and unvaccinated Ugandan girls.
Methods: We conducted a cross sectional study among AS04-adjuvanted HPV-16/18 vaccinated and unvaccinated
school girls aged 10–16 years in Western Uganda using purposive sampling. The vaccinated girls were at 18 months
post vaccination. After consenting and assenting, data was collected using interviewer administered questionnaires
for demographics and sexual history. Blood was drawn from which serum samples were analysed by the multiplex
HPV serology technology to determine anti-HPV antibody levels to HPV-16/18 and six other hrHPV types (31, 33, 35,
45, 52 and 58). The antibody levels were expressed as Median Fluorescent Intensity (MFI).
A total of 207 vaccinated [mean age 13.1 years (SD 1.5); range 10-16 years] and 197 unvaccinated girls [mean age
13.6 years (SD 1.3); range 10-16 years] participated in the study. Sexual activity was self reported among 14/207
(6.8%) vaccinated and 5/197 (2.5%) unvaccinated girls. The MFI levels for HPV-16 and HPV-18 were 15 and 20
times higher respectively in the vaccinated girls than in the unvaccinated girls. HPV-16 mean MFI level was 4691
(SD 1812; 95% CI: 4438-4958) among the vaccinated compared to 218 (SD 685; 95% CI: 190-252) among the
unvaccinated girls. For HPV-18 the mean MFI level was 1615 (SD 1326; 95% CI: 1470-1776) among the vaccinated
compared to MFI 103 (SD 506; 95% CI: 88 -121) among unvaccinated girls.
In addition antibody levels to non vaccine hrHPV types (31, 33, 35, 45, 52 and 58) were all significantly higher in the
vaccinated group than in the unvaccinated group (p<0.01).
Conclusion: The AS04-Adjuvanted HPV-16/18 vaccinated girls showed a higher level of antibodies to HPV-16/18
and other non-vaccine hrHPV types compared to the unvaccinated girls. This may translate into protection against
HPV-16/18 and other hrHPV types.
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Cervical cancer is the second most common cancer in
women worldwide and the primary cause of cancer re-
lated deaths among women in the developing countries
[1]. More than 84% of the estimated 528,000 incident
cases that occur annually and more than 88% of the
257,000 deaths caused by cervical cancer occur in devel-
oping countries [2]. This makes cervical cancer a major
cause of morbidity and mortality in the developing
world. The substantial difference in incidence and mor-
tality between the developed and developing world [3] is
mainly due to lack of established screening programs
and early detection interventions [4]. This demonstrates
a clear need for alternative cervical cancer prevention
interventions.
Human Papilloma Virus (HPV) is the most common
sexually transmitted infection and has been recognized
as the necessary cause of cervical cancer [5]. In Uganda,
HPV infection is common among both HIV negative
and positive young women aged below 25 years with
prevalence of ‘high risk’ HPV (hrHPV) genotypes ran-
ging from 41.6% - 75.0% and 23.7% - 67.1% respectively
according to a recent review [6]. Therefore, prevention
of HPV infection is a critical step in reducing the burden
of cervical cancer.
The recently developed prophylactic vaccines against
HPV infection are more than 90% effective in preventing
infection and high-grade pre-cancer lesions associated
with HPV types included in the vaccine [7]. Currently,
Uganda has endorsed HPV vaccination as one of the
strategies for cervical cancer prevention with the second
phase of the national vaccination program about to be
rolled out by 2015. In comparison to the developed
countries, data on the immunogenicity and safety of the
vaccine in Sub-Saharan Africa is still sparse [8] despite a
number of African countries approving use of the HPV
vaccine.
Therefore, a cross sectional study was conducted in
Western Uganda to compare levels of antibodies to
HPV-16/18 and other hrHPV types among vaccinated




The results represent two groups, vaccinated and unvac-
cinated girls. A total of 375 and 425 girls from the
vaccinated and unvaccinated districts, respectively, were
present in the schools on the days of the survey. Of
these, 211/375 (56.3%) and 200/425 (47%) vaccinated
and unvaccinated girls assented and had parental con-
sent to participate in the study, respectively (Figure 1).
Out of the total 411 vaccinated and unvaccinated girls
who consented and assented, 404 (98.2%) had adequateserum samples for antibody analysis. Only girls with
adequate serum samples were included in the statistical
analysis (vaccinated n = 207: mean age 13.1 years (SD
1.5); range 10–16 years: Non vaccinated n = 197: mean
age 13.6 yrs (SD 1.28) range 10–16 years) (Table 1). In
both districts, most girls [170/207 (82.2%)] among the
vaccinated group and [155/197(78.7)] among the unvac-
cinated group were 10–14 years old.
Sexual activity
Overall 19/404 (4.7%) of the girls self reported engaging
in penetrative sexual activity. Among those who self
reported engaging in sexual activity, 14/207 (6.8%) were
vaccinated while 5/197 (2.7%) were unvaccinated girls.
Overall, the median age at sexual debut was 11 yrs;
range 6–13 years (vaccinated 10.9 years while unvaccin-
ated 12.5 years; Table 1).
Immunogenicity
The MFI level for HPV-16 and HPV-18 at month 18 post
vaccination was 15 and 20 times respectively higher among
the vaccinated girls than the unvaccinated girls (Figure 2).
HPV-16 mean MFI level was 4691 (SD 1812; 95% CI: 4438–
4958) among the vaccinated compared to 218 (SD 685; 95%
CI: 190–252) among the unvaccinated girls. For HPV-18
mean MFI level was 1615 (SD 1326; 95% CI: 1470–1776)
among the vaccinated compared to 103 (SD 506; 95% CI:
88–121) among the unvaccinated girls (Table 2).
There was no difference in the MFI levels for anti HPV-
16/18 between vaccinated girls who were 10–14 years and
those who were 15 years and older: HPV-16 (p =0.47);
HPV-18 (P = 0.1) (Figure 3). Likewise, among the unvac-
cinated girls, there was no difference in the MFI levels for
anti HPV-16/18 between the self reported sexually active
and those who didn’t report. HPV 16 (p =0.43); HPV-18
(P = 0.58) (Figure 4).
Further, the transformed MFI levels to other non vac-
cine hrHPV-31, 33,35,45,52 and 58 were all significantly
higher among the vaccinated than the unvaccinated girls
(Table 2).
Discussion
This is one of the few studies so far evaluating antibody
responses to the bivalent AS04-adjuvanted HPV-16/18
vaccine in Sub-Saharan Africa. We observed a higher
level of antibodies to HPV-16/18 and other non vaccine
hrHPV types 31, 33, 35, 45, 52, 58 among the vaccinated
girls when compared to the unvaccinated ones. By com-
paring vaccinated girls with unvaccinated girls in this
study, we were able to demonstrate that vaccination with
the bivalent AS04-adjuvanted HPV-16/18 vaccine may
have been responsible for the high antibody levels to the
vaccine hrHPV-16/18 and other non vaccine hrHPV
types in this population of girls.
Figure 1 Flow diagram of vaccinated and unvaccinated girls who participated in the study. A total of 375 and 425 girls from the
vaccinated and unvaccinated districts were present in the schools on the days of the survey. Of those present, 211/375(56.3%) vaccinated and
200/425(47%) unvaccinated girls were recruited in the study. The vaccinated girls were at months 18 post vaccination. In the laboratory, 207/211
(98%) and 197/200(98.5%) serum samples from the vaccinated and unvaccinated girls were adequate for analysis respectively.
Table 1 Socio-demographic and sexual characteristics of vaccinated and unvaccinated girls
Variable Vaccinated n = 207 Unvaccinated n = 197 P value
n % n %
Age 0.001
10-14 years 170 (82.2) 155 (78.7)
≥15 years 37 (17.9) 42 (21.3)
School Location 0.001
Rural 76 (36.7) 155 (78.7)
Urban 130 (63.3) 42 (21.3)
Self reported sexually active 0.045
Yes 14 (6.8) 5 (2.5)
No 193 (93.2) 192 (97.5)
Age group of sexually active: n = 14 vaccinated; unvaccinated n = 5 0.31
10-14 years 11 (78.6) 2 (40)
≥15 years 3 (21.4) 3 (60)
Age group of first sexual encounter: n = 161 0.21
10-14 years 11 (100) 4 (75)
≥15 years 0 (0) 1 (25)
Socio demographic and sexual characteristics of vaccinated and unvaccinated girls. Mean age for vaccinated and unvaccinated girls was 13.1 yrs (SD 1.5; range
10–16 years) and 13.6 yrs (SD 1.3; range 10–16 years) (p <0.001), respectively.
Overall 19/385 (4.9%) girls self reported engaging in penetrative sexual activity. Fourteen girls (14/207; 6.8%) were vaccinated girls while 5/197 (2.5%) were
unvaccinated girls. Median age of sexual debut was 11 years (range 6–13); vaccinated 10.9 years while unvaccinated 12.5 years. There was significant difference in
sexual activity between the girls who were vaccinated and unvaccinated (p < 0.001).
1Data on age of first sexual encounter for 3 girls is missing.
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Figure 2 Comparison of the MFI antibody levels to HPV-16 and HPV-18 at month 18 post vaccination among the vaccinated girls and
the unvaccinated girls. The MFI levels for HPV-16 and HPV-18 among the vaccinated girls were over 20 and 15 times higher respectively among
vaccinated than the unvaccinated girls. The central line represents the median MFI levels; above and below the median line in the box are the
75th and 25th centiles; the whiskers represent the upper and lower MFI values and the dots represent the outlier value. The outlier values were
calculated using the z –scores (standardizing the data) with an absolute value of z as 1.96. There were 13/207(6.3%) and 11/197(5.5%) vaccinated
and unvaccinated girls respectively with outlier values of antibody levels to HPV-16. For HPV-18, 11/207 (5.3%) and 6/197(3%) from the unvaccinated
group had outlier values. For both HPV-16/18, the girls who had outlier values were comparable in terms of age and sexual activity.
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vaccinated girls in our study agrees with the results of
immunogenicity studies among HIV negative girls from
sub-Saharan Africa as well as other parts of the world
[8-10]. Although there is not yet published data showing
levels of antibodies to HPV-16/18 vaccine using theTable 2 Showing the MFI log10 transformed antibodies
to HPV-16/18 and other hrHPV types among vaccinated
and unvaccinated girls
Vaccinated month
18 (n = 207)
Unvaccinated
(n = 197)
MFI (95% CI) MFI (95% CI) P-value
HPV16 4691.4(4438.1-4957.9) 218.5(189.7-251.6) <0.001
HPV18 1615.5(1469.6-1775.8) 103.3(88.1-121.3) <0.001
HPV31 844.9(750.1-951.5) 251(211.3-298.3) <0.001
HPV33 444(399.3-493.6) 245.7(215.2-280.5) <0.001
HPV35 752(661.3-854.9) 185.2(158.7-216.1) <0.001
HPV45 634.6(563.2-715.2) 127.6(111.7-145.7) <0.001
HPV52 640.2(570.4-718.5) 260.6(231–294) <0.001
HPV58 404.9(364.6-449.5) 229.1(207.3-253.3) <0.001
Comparing means of MFI log10 transformed antibodies to HPV-16/18 and other
hrHPV types among vaccinated and unvaccinated girls. The mean of the
MFI levels to other non vaccine hrHPV-31, 33, 35, 45, 52 and 58 were all
significantly higher among the vaccinated than the unvaccinated girls when
compared antibodies at month 18 post vaccination.multiplex serological method, this method still demon-
strated HPV-16/18 antibody levels that were many times
higher among the vaccinated girls as compared to those
observed among the unvaccinated girls. This trend of
antibody levels higher than natural infection expressed
as geometric mean titres has been demonstrated in one
of the longest follow up studies of the bivalent HPV-16/
18 vaccine using ELISA by the vaccine manufacturers
(GlaxoSmithKline (GSK) Biologicals) [11].
Furthermore, results of this study have showed higher
antibody levels to non vaccine hrHPV types 31, 33, 35,
45, 52, 58 among the vaccinated girls as compared to
the unvaccinated girls. This observation is in line with
what has already been documented in other studies that
HPV-16/18 vaccine induces cross-neutralising antibodies
that may offer cross protection among phylogenetically
related HPV types (α7 (HPV18 and 45) or α9 (HPV16,
31, 33, 52 and 58) [12,13]. Likewise in this study, the ob-
served antibody levels to the non vaccine hrHPV types
may translate into cross protection. However, because
the immune correlates of protection to all the hrHPV
types are yet to be determined, the results from this study
may not conclude on the issues of cross protection.
In previous trials, the strong vaccine induced immune
response has been proved to protect against persistent
HPV-16/18 infections and CIN disease [9,10]. We as-
sume that the much higher immune response observed
Figure 3 Comparing the median of antibody levels to anti HPV-16/18 among 10–14 year old and those ≥15 years old vaccinated girls.
The central line represents the median of the MFI levels; above and below the median line in the box are the 75th and 25th centiles; the whiskers
represent the upper and lower MFI values and the dots represent the outlier value
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terparts may translate into protection against HPV infec-
tion, CIN and eventually cervical cancer. However it will
be many years before this is realised, therefore there is
need for close follow up especially in this environment
where cervical cancer is very prevalent.
The high level of immune response to the vaccine seen
in this study may support the idea of fewer doses in thisFigure 4 Comparing the median antibody values to anti HPV-16/18 u
those who were not. The central line represents the median of the MFI le
25th centiles; the whiskers represent the upper and lower MFI values and thage group as has been endorsed by the World Health
Organisation (WHO) [14] though this study did not
investigate the immune response according to different
doses. Further, in Africa as elsewhere, the duration of
protection as well as the immune correlate of protection
is yet to be known. Therefore, as HPV vaccination pro-
grams continue to be rolled out in Africa, it is necessary
to continue monitoring HPV-16/18 vaccine performancenvaccinated girls who self reported being sexually active and
vels; above and below the median line in the box are the 75th and
e dots represent the outlier value.
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vaccination schedules all over the region.
The girls were at the same school level in the different
schools although there was a significant difference in
their age and sexual activity. The vaccinated girls were
mainly from around the urban area and tended to be
younger. This observation is in line with what is already
known that Ugandan children from rural settings tend
to start school at an older age than their urban counter-
parts [15]. Further, our study shows evidence of sexual
activity below the Uganda national mean age of sexual
debut which is 17.5 years. However, this national age of
sexual debut is from a larger sample size stretching over
a wider age range as compared to the girls who partici-
pated in our study. The finding of sexual activity in this
age group is consistent with results of other studies
which showed that in Uganda and other sub-Saharan
countries 6%-11.1% of girls in the age range of 10–15
years had already initiated sex [16,17]. Though the girls
from the vaccinated district tended to be younger, they
were more likely to have engaged in sex as compared to
the unvaccinated girls. The level of self reported sexual
activity observed among the unvaccinated girls in our
study agrees with what has been documented in a recent
publication [18] where 2.5% of the unvaccinated girls
from another district volunteered information that they
were sexually active. However unlike the results of our
study, this publication did not find a difference in sexual
behaviour among the girls who were vaccinated and
those who were not. The difference in this finding
between the two studies may be due to the different
cultural settings as well as location of the girls in terms
of urban and rural despite the girls being of a similar age
group and HPV vaccination status.
Among the unvaccinated group, when sexually active
girls were compared with those who were not, there was
no difference in MFI levels to both HPV-16/18. The
sexually active girls may not have been exposed to HPV-
16/18 despite the sexual activity. Further, it is known
that about 50% of those exposed to HPV infection may
not mount an immune response [19] which may explain
the lack of difference in MFI levels. In addition, our
study had few numbers that self reported sexual activity.
Finally, self reporting sexual activity may not be a very
reliable way of assessing this factor as has been docu-
mented in other studies [20,21].
Association between sexual activity and levels of anti-
bodies to HPV-16/18 was not assessed for the vaccinated
girls as results from some studies [8,22] so far have
showed that natural exposure to HPV-16/18 may not
influence immune response to the HPV-16/18 vaccine.
Further, evidence [8,23] shows that girls in the age range
of 10–14 years had higher antibody titres to the HPV
vaccine than those 15 years and above an observationthat was not evident in our study. However, in the
studies above, the age span of the study participants was
longer (15–25 years) with more numbers whereas in our
study the age span was only 15–16 years with fewer
girls. The difference in the age ranges (15–16 versus 15–
25 years) together with the fewer numbers in our study
may explain why we have not seen a difference in vac-
cine induced antibody levels as far as age is concerned.
This study had some limitations. The antibody levels
were only assessed at one time point. There was no
baseline antibody level from the vaccinated girls before
vaccination. However for a similar picture of levels of
anti-HPV16/18 after natural exposure to HPV-16/18 a
group of girls from a neighboring district who would
have been vaccinated at the same time were chosen
to participate in this study as a comparative group.
This inclusion of the unvaccinated group of girls also
enabled a demonstration of a difference in antibody
levels which could only be explained by vaccination.
The girls were of unknown HIV status. This is the
situation that will happen in normal vaccination pro-
grams; HIV status will not be exclusion for the HPV
vaccine. The method used for HPV serological analysis
is not yet widely used to monitor HPV vaccine im-
munogenicity and comparison with other studies may
be difficult, however comparison by trends of antibody
levels may be appropriate for future follow up even
when different methods are used.
Conclusion
The AS04-adjuvanted HPV-16/18 vaccinated girls showed
a higher level of antibodies to HPV-16/18 and other non-
vaccine hrHPV types compared to the unvaccinated girls.
These results support continued use of the prophylac-
tic HPV-16/18 vaccine in Africa where for decades there
has been no success with any screening program against
cervical cancer, an intervention that has helped to sig-
nificantly reduce cervical cancer in the developed world.
Therefore for African countries, effective HPV vaccin-
ation programs seem to be the window of opportunity
to reduce cervical cancer mortality and morbidity. By
assessing both vaccinated and unvaccinated girls, we are
able to provide insight in the immunological response to
the HPV-16/18 vaccine as well as provide baseline
knowledge of HPV-16/18 and other hrHPV types after
natural exposure. It is also evident from this study that
some girls initiate sex earlier than expected therefore
efforts to vaccinate girls at the earliest WHO recom-
mended age of 9 years [14] should be promoted. The
knowledge generated from this study is important for
future vaccine monitoring and implementation. Follow
up studies to assess the immunogenicity of the vaccine
over time are recommended since it will be many years
before the effect of the vaccine is realized [24].
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Study design
We conducted a cross sectional survey between October
2011-February 2012 among HPV vaccinated and unvac-
cinated girls at 18 months post vaccination. The study
was approved by the higher degrees research and ethics
committee (HDREC) of Makerere University College of
Health Sciences and finally by the Uganda National
Council for Science and Technology (UNCST). Permis-
sion was sought from the local government in the dis-
tricts of study and school authorities. Consent from the
parents/guardians of the girls as well as assent from the
girls were obtained.
Study site
The study was conducted within two neighbouring
districts of Western Uganda, Ibanda (vaccinated district)
and Mbarara (unvaccinated) between October 2011-
February 2012. Ibanda district covers an area of 967
square kilometres (373 sq mi) with one county and
seven sub counties. It has an estimated population of
242,800 people. The vaccination exercise that was
carried out was school based and targeted pupils form
primary level 4 at an assumed age of 9 years. Mbarara
district covers an area of 1,846.4 square kilometres
(712.9 sq mi) with 4 counties and 19 sub counties. It has
an estimated total population is about 457,800 people.
At the time of the study, Ibanda had 180 primary
schools with approximately 23,695 pupils out of which
6,770 (28.5%) pupils had been eligible for HPV-16/18
vaccination in 2010 by the PATH (Program for Appro-
priate Technology in Health) demonstration project.
Mbarara district had 402 primary schools with about
50,307 pupils out which about 11,053 (21.9%) would
have been eligible for vaccination in 2010 had the
program covered Mbarara district.
Selection of sub-counties
One sub-county from each district was purposively
selected. The selection was based on the population of
girls in primary level 5 being at least 500 girls in the
sub-county. In addition, the sub-county had to be ac-
cessible to the main road so that blood samples could
easily be delivered daily to the laboratory for processing.
Selection of schools and girls in the vaccinated district
There were 29 schools in the selected sub-county of
Ibanda out of which 15(51%) schools participated in the
study. The schools were listed according to the number of
eligible girls in descending order. Letters introducing the
study and requesting for permission to carry out the study
in the district schools were sent out to the district leaders.
After receiving permission from the district leadership,
phone contacts were made to the head teachers brieflyexplaining the study. Community mobilisers then visited
all the schools within each sub county to deliver letters
introducing the study and requesting for permission from
the head teachers to have their schools participate in the
study. A convenient day for the study team to visit the
school was agreed upon. The mobilisers carried HPV
vaccination registers from the district to verify the vaccin-
ation status of the girls who had been vaccinated in 2010.
The head teachers were requested to invite the parents/
guardians of the girls who had complete vaccine doses
according to the register. On the day of the school visit,
trained research assistants and the principal investigator
(PI) explained the study to the girls and their parents/
guardians in separate sessions. The explanations included
the objectives of the study and procedures which involved
answering a questionnaire and providing a blood sample.
After the explanations and responding to questions, writ-
ten informed consent from parents/guardians (guardians
above 18 years) was obtained. In addition, a written assent
from the girls whose parents had consented was also
obtained. All girls who were fully vaccinated in 2010 and
attending schools from within the selected sub-counties
were eligible to participate. The girls were consecutively
recruited until the desired sample size was realised.
Selection of schools and girls in the unvaccinated district
Girls were eligible to participate if they were in the same
class as the vaccinated ones and not repeaters of the
same class. There were 34 schools in the selected sub-
county of Mbarara out of which 17(50%) schools were
involved in the study. The selection of the schools and
visit procedures were similar to those employed in the
vaccinated district. However, since the district had not
participated in the vaccination program, there were no
vaccine registers. Inquiry with the class teachers was
made if any of the girls had previously been in the vacci-
nated district. A school register was used in addition to
the information from the girls to verify the class level.
Study procedures
In the vaccinated district, girls who were fully vaccinated
(received 3 doses) in 2010 with assent and consent partici-
pated in the study. In the unvaccinated district only girls
who would have been eligible to HPV vaccination at the
same time as in the vaccinated district with assent and
consent participated in the study. All the girls both vacci-
nated and unvaccinated answered an interviewer adminis-
tered questionnaire that included sections on socio-
demographic characteristics, vaccination status, general
medical history and sexual history. The age was self
reported by the girls and recorded as actual age at the
time of the survey. Sexual activity was defined as having
penetrative vaginal or anal sexual intercourse with the op-
posite sex. A blood sample was collected from both the
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blood sample was collected under aseptic conditions.
Blood sample collection
The study laboratory technician, nurses and PI carried
out the blood draws from the girls. In a sitting position,
the girl’s non dominant hand was identified. Following
identification of the vein in the cubital fossa, the area
was cleaned with 70% alcohol swab. Two-three millilitres
(mls) of blood were aseptically collected from the cubital
vein into a labelled SST™ tube.
The vials of blood were put in transport boxes that
had ice boxes and transported to Mbarara University
Epicenter laboratory within 2–8 hours of collection. In
the laboratory, the vials of blood were centrifuged for
15 minutes at 1000xg immediately on arrival. One
millilitre of serum was aliquoted into pre-labelled 2 ml
screw capped eppendorf tubes and temporarily stored
at −80°C in Mbarara University Epicenter laboratory.
Serum samples were then transported on dry ice to the
Molecular laboratory at the Makerere University College
of Health Sciences and kept at −80°C until shipping on
dry ice to Germany Cancer Research Center (DKFZ) in
Heidelberg.
Serological evaluation for HPV antibodies
Antibodies to the L1 proteins of 8 hrHPV types (16, 18,
31, 33, 35, 45, 52, and 58) were analyzed using a multiplex
serology method. This method is based on a Glutathione
S-transferase capture immunosorbent assay combined
with fluorescent-bead technology as described elsewhere
[25-27].
Procedure for estimating the HPV antibodies
Bead sets carrying different antigens were mixed and incu-
bated with an equal volume of the serum dilutions (2 μl)
in a 96 well plate. Human antibodies bound to their
respective antigens were stained with a secondary biotinyl-
ated goat-anti human immunoglobulin IgG (Dianova,
Hamburg, Germany) and the fluorescent reporter conju-
gate streptavidin-R-phycoerythrin. A Luminex100analyzer
(Luminex100 IS™ by Luminex Corporation 12212 Techno-
logyBlvd. Austin, Texas 78727; http://www.luminexcorp.
com) determined the internal bead colour specific for the
respective antigen and reporter fluorescence of the beads,
reflecting the quantity of antibodies recognizing the re-
spective antigens. For each bead set the reporter fluores-
cence was expressed as median fluorescence intensity
(MFI) of at least 100 beads per set per serum. Final
antigen-specific MFI values were calculated by subtraction
of Glutathione S-Transferase Fusion Proteins-tag (GST)
and an individual bead background value. MFI were ob-
tained for vaccine HPV-16/18 as well as non vaccine high
risk HPV (hrHPV) 31, 33, 45, 52, 58. For proteins of HPVtypes (HPV 16, 18, 31, 33, 35, 45, 52, 58) cut-offs were
calculated as mean plus 3 SD of sera from HPV negative
controls. The MFI cut-offs were; 373, 200, 303, 200, 200,
200, 297, 275 for hrHPV types 16, 18, 31, 33, 35, 45, 52, 58
respectively.
Sample size calculation
A sample size of 199 in each group would have 80% power
to detect a difference in means of 4024.000 (the difference
between a Vaccinated group mean, μ1 of 4029.000 and
unvaccinated group mean, μ2, of 5.000) assuming that the
common standard deviation is 14263.000 using a two
group t-test with a 0.050 two-sided significance level [13].
We assumed 30% of the girls would either be absent
or not have consent/assent; and that an additional 14%
of the girls would have incomplete doses [28].
Therefore with the above assumptions, the target popula-
tion would be at least 260 girls from Mbarara district (con-
trol district) and 288 girls from Ibanda district (Vaccinated).
Data analysis
The data were analysed using SPSS V20 (SPSS Hong
Kong Ltd, Rm 1804, 18/F, Westlands Centre, Westlands
Road, Quarry Bay, Hong Kong). At univariate analysis,
categorical data were summarized using percentages
while continuous variables were summarized by calculat-
ing the mean, standard deviation, median, range. Calcu-
lation of p values for mean comparison of age was done
using Mann–Whitney U test while sexual activity be-
tween the two groups was compared using Pearson-chi
square and Fishers exact test (p < 0.05significant).
MFI levels of antibodies to HPV-16/18 and other
hrHPV types showed skewed distribution therefore the
HPV antibody levels were transformed as Log10 (MFI
levels for antibody concentration). We compared the
mean of the MFI values between vaccinated and unvac-
cinated girls with the students t test. The mean of the
MFI levels and corresponding 95% CI were calculated.
Box plots present the distribution of the MFI values for
HPV-16/18 antibodies levels among the vaccinated and
unvaccinated girls at month 18 post vaccination. The
median of the MFI values for the box plots was com-
pared with the Mann–Whitney U test. In addition effect
of age and sexual activity was compared to the median
antibody levels among vaccinated girls and unvaccinated
girls respectively. Significance level was set at p <0.05.
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